ALRN Aileron Therapeutics | $3.20 -0.3% | 5/30/2024 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Strong-Buy | | Low | View details for Brookline Capital Management rating of Aileron Therapeutics (NASDAQ:ALRN) on 5/30/2024 |
FBRX Forte Biosciences | $0.59 -5.0% | 5/30/2024 | Initiated by | Brookline Capital Management | - | Buy | $4.00 | Low | View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 5/30/2024 |
DARE Daré Bioscience | $0.41 -4.8% | 5/15/2024 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Hold -> Buy | $3.00 | Low | View details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 5/15/2024 |
DARE Daré Bioscience | $0.41 -4.8% | 4/17/2024 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | N/A | View details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 4/17/2024 |
IMUX Immunic | $1.24 +1.6% | 4/5/2024 | Reiterated by | Brookline Capital Management | Analyst T. Bussian | Buy | $10.00 | Low | View details for Brookline Capital Management rating of Immunic (NASDAQ:IMUX) on 4/5/2024 |
FUSN Fusion Pharmaceuticals | $21.52 +0.2% | 3/19/2024 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | N/A | View details for Brookline Capital Management rating of Fusion Pharmaceuticals (NASDAQ:FUSN) on 3/19/2024 |
|
ATE Antibe Therapeutics | C$0.30 +13.5% | 3/4/2024 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | N/A | View details for Brookline Capital Management rating of Antibe Therapeutics (TSE:ATE) on 3/4/2024 |
ATBPF Antibe Therapeutics | $0.22 +13.5% | 3/4/2024 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | Low | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 3/4/2024 |
ANVS Annovis Bio | $6.55 +9.2% | 2/28/2024 | Downgraded by | Brookline Capital Management | Analyst T. Bussian | Buy -> Hold | $9.00 | Low | View details for Brookline Capital Management rating of Annovis Bio (NYSE:ANVS) on 2/28/2024 |
OTLK Outlook Therapeutics | $7.07 -2.1% | 1/25/2024 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Hold -> Buy | $31.40 | Low | View details for Brookline Capital Management rating of Outlook Therapeutics (NASDAQ:OTLK) on 1/25/2024 |
ONCT Oncternal Therapeutics | $9.21 +1.2% | 12/4/2023 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Hold -> Buy | $40.00 | Low | View details for Brookline Capital Management rating of Oncternal Therapeutics (NASDAQ:ONCT) on 12/4/2023 |
LNTH Lantheus | $81.83 +1.6% | 11/30/2023 | Initiated by | Brookline Capital Management | - | Buy | $100.00 | Low | View details for Brookline Capital Management rating of Lantheus (NASDAQ:LNTH) on 11/30/2023 |
ANVS Annovis Bio | $6.55 +9.2% | 11/10/2023 | Reiterated by | Brookline Capital Management | Analyst T. Bussian | Buy | $35.00 | Low | View details for Brookline Capital Management rating of Annovis Bio (NYSE:ANVS) on 11/10/2023 |
GNLX Genelux | $2.71 +2.3% | 10/30/2023 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Hold -> Buy | | Low | View details for Brookline Capital Management rating of Genelux (NASDAQ:GNLX) on 10/30/2023 |
EYEN Eyenovia | $0.81 +13.5% | 10/17/2023 | Initiated by | Brookline Capital Management | - | Buy | $8.00 | Low | View details for Brookline Capital Management rating of Eyenovia (NASDAQ:EYEN) on 10/17/2023 |
EDSA Edesa Biotech | $4.33 -1.6% | 10/12/2023 | Reiterated by | Brookline Capital Management | - | Buy -> Buy | $57.00 | Low | View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 10/12/2023 |
OTLK Outlook Therapeutics | $7.07 -2.1% | 8/30/2023 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | Low | View details for Brookline Capital Management rating of Outlook Therapeutics (NASDAQ:OTLK) on 8/30/2023 |
ATBPF Antibe Therapeutics | $0.22 +13.5% | 8/14/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 8/14/2023 |
ONCT Oncternal Therapeutics | $9.21 +1.2% | 4/3/2023 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | Low | View details for Brookline Capital Management rating of Oncternal Therapeutics (NASDAQ:ONCT) on 4/3/2023 |
ONCT Oncternal Therapeutics | $9.21 +1.2% | 3/9/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Oncternal Therapeutics (NASDAQ:ONCT) on 3/9/2023 |
DARE Daré Bioscience | $0.41 -4.8% | 2/14/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 2/14/2023 |
FUSN Fusion Pharmaceuticals | $21.52 +0.2% | 2/13/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Fusion Pharmaceuticals (NASDAQ:FUSN) on 2/13/2023 |
ECOR electroCore | $6.43 -2.0% | 1/12/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | View details for Brookline Capital Management rating of electroCore (NASDAQ:ECOR) on 1/12/2023 |
IMNN Imunon | $1.44 -1.4% | 11/14/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Imunon (NASDAQ:IMNN) on 11/14/2022 |
VXRT Vaxart | $0.82 +0.1% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Vaxart (NASDAQ:VXRT) on 10/3/2022 |
OTLK Outlook Therapeutics | $7.07 -2.1% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Outlook Therapeutics (NASDAQ:OTLK) on 10/3/2022 |
MNPR Monopar Therapeutics | $0.61 -0.2% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 10/3/2022 |
LSTA Lisata Therapeutics | $2.94 -5.8% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Lisata Therapeutics (NASDAQ:LSTA) on 10/3/2022 |
IMNN Imunon | $1.44 -1.4% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Imunon (NASDAQ:IMNN) on 10/3/2022 |
EDSA Edesa Biotech | $4.33 -1.6% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 10/3/2022 |
ATE Antibe Therapeutics | C$0.30 +13.5% | 8/15/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | View details for Brookline Capital Management rating of Antibe Therapeutics (TSE:ATE) on 8/15/2022 |
ARCT Arcturus Therapeutics | $38.81 +0.9% | 8/10/2022 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/10/2022 |
ATBPF Antibe Therapeutics | $0.22 +13.5% | 6/30/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 6/30/2022 |
VERU Veru | $1.01 +4.5% | 5/18/2022 | Target Raised by | Brookline Capital Management | Analyst Kumaraguru Raja | Buy -> Buy | $29.00 -> $31.00 | Medium | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 5/18/2022 |
VRCA Verrica Pharmaceuticals | $8.51 +2.2% | 3/10/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Medium | View details for Brookline Capital Management rating of Verrica Pharmaceuticals (NASDAQ:VRCA) on 3/10/2022 |
NTLA Intellia Therapeutics | $21.38 -3.3% | 3/7/2022 | Upgraded by | Brookline Capital Management | Analyst L. Cann | Hold -> Buy | $91.00 | High | View details for Brookline Capital Management rating of Intellia Therapeutics (NASDAQ:NTLA) on 3/7/2022 |
CRSP CRISPR Therapeutics | $53.74 -0.6% | 2/14/2022 | Reiterated by | Brookline Capital Management | Analyst Leah Rush | Buy | $143.00 | High | View details for Brookline Capital Management rating of CRISPR Therapeutics (NASDAQ:CRSP) on 2/14/2022 |
NTLA Intellia Therapeutics | $21.38 -3.3% | 2/14/2022 | Reiterated by | Brookline Capital Management | Analyst Leah Rush | Buy | | Low | View details for Brookline Capital Management rating of Intellia Therapeutics (NASDAQ:NTLA) on 2/14/2022 |
CRBU Caribou Biosciences | $2.88 +1.1% | 2/14/2022 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | | Medium | View details for Brookline Capital Management rating of Caribou Biosciences (NASDAQ:CRBU) on 2/14/2022 |
FUSN Fusion Pharmaceuticals | $21.52 +0.2% | 2/2/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Medium | View details for Brookline Capital Management rating of Fusion Pharmaceuticals (NASDAQ:FUSN) on 2/2/2022 |
Are You Positioned For The New Energy Goldrush? (Ad) Open AI’s Sam Altman recently helped this company raise $577 million in funding…
What’s more is, It has already inked deals with the Department of Energy.![](https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8003&Placement=NativeDisplay&Source=NativeDisplay) Click here to get all the information about it. |
ICCM IceCure Medical | $1.07 +0.9% | 2/1/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of IceCure Medical (NASDAQ:ICCM) on 2/1/2022 |
DARE Daré Bioscience | $0.41 -4.8% | 1/19/2022 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 1/19/2022 |
KYMR Kymera Therapeutics | $32.11 -0.2% | 10/13/2021 | Reiterated by | Brookline Capital Management | Analyst Leah Rush Cann | Buy | $80.00 | Medium | View details for Brookline Capital Management rating of Kymera Therapeutics (NASDAQ:KYMR) on 10/13/2021 |
FBRX Forte Biosciences | $0.59 -5.0% | 9/3/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Hold | | Low | View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 9/3/2021 |
VERU Veru | $1.01 +4.5% | 8/27/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Medium | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 8/27/2021 |
SCYX SCYNEXIS | $2.41 +2.6% | 8/24/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 8/24/2021 |
CCCC C4 Therapeutics | $5.00 +0.4% | 6/25/2021 | Reiterated by | Brookline Capital Management | Analyst Leah Rush Cann | Buy | | High | View details for Brookline Capital Management rating of C4 Therapeutics (NASDAQ:CCCC) on 6/25/2021 |
ATE Antibe Therapeutics | C$0.30 +13.5% | 6/3/2021 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | View details for Brookline Capital Management rating of Antibe Therapeutics (TSE:ATE) on 6/3/2021 |
ATBPF Antibe Therapeutics | $0.22 +13.5% | 6/3/2021 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Medium | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 6/3/2021 |
MNPR Monopar Therapeutics | $0.61 -0.2% | 5/25/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Medium | View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 5/25/2021 |
BIOX Bioceres Crop Solutions | $11.78 +4.1% | 5/7/2021 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | View details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 5/7/2021 |
SQZ SQZ Biotechnologies | $0.44 +61.1% | 3/30/2021 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | | N/A | View details for Brookline Capital Management rating of SQZ Biotechnologies (NYSE:SQZ) on 3/30/2021 |
ONCT Oncternal Therapeutics | $9.21 +1.2% | 3/30/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | $320.00 | High | View details for Brookline Capital Management rating of Oncternal Therapeutics (NASDAQ:ONCT) on 3/30/2021 |
MRNA Moderna | $142.55 -5.9% | 2/26/2021 | Target Raised by | Brookline Capital Management | - | Buy | $180.00 -> $205.00 | Low | View details for Brookline Capital Management rating of Moderna (NASDAQ:MRNA) on 2/26/2021 |
XFOR X4 Pharmaceuticals | $1.01 +3.5% | 12/17/2020 | Initiated by | Brookline Capital Management | Analyst L. Cann | Buy | $21.00 | High | View details for Brookline Capital Management rating of X4 Pharmaceuticals (NASDAQ:XFOR) on 12/17/2020 |
VERU Veru | $1.01 +4.5% | 12/14/2020 | Target Raised by | Brookline Capital Management | Analyst K. Raja | | $13.00 -> $17.00 | High | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 12/14/2020 |
SYRS Syros Pharmaceuticals | $5.10 +2.0% | 11/10/2020 | Initiated by | Brookline Capital Management | Analyst L. Cann | Buy | $190.00 | Low | View details for Brookline Capital Management rating of Syros Pharmaceuticals (NASDAQ:SYRS) on 11/10/2020 |
ECOR electroCore | $6.43 -2.0% | 10/23/2020 | Initiated by | Brookline Capital Management | Analyst S. Yanchus | Buy | $75.00 | Low | View details for Brookline Capital Management rating of electroCore (NASDAQ:ECOR) on 10/23/2020 |
AWH Aspira Women's Health | $2.47 +14.9% | 10/14/2020 | Reiterated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | High | View details for Brookline Capital Management rating of Aspira Women’s Health (NASDAQ:AWH) on 10/14/2020 |
MEIP MEI Pharma | $2.86 -1.4% | 10/12/2020 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | | Medium | View details for Brookline Capital Management rating of MEI Pharma (NASDAQ:MEIP) on 10/12/2020 |
DMTK DermTech | $0.32 -1.7% | 9/11/2020 | Initiated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | High | View details for Brookline Capital Management rating of DermTech (NASDAQ:DMTK) on 9/11/2020 |
FBRX Forte Biosciences | $0.59 -5.0% | 8/28/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $90.00 | Low | View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 8/28/2020 |
HUGE FSD Pharma | $0.30 -3.2% | 8/20/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of FSD Pharma (NASDAQ:HUGE) on 8/20/2020 |
HUGE FSD Pharma | $0.30 -3.2% | 8/20/2020 | Initiated by | Brookline Capital Management | - | Buy | $11.00 | N/A | View details for Brookline Capital Management rating of FSD Pharma (NASDAQ:HUGE) on 8/20/2020 |
KURA Kura Oncology | $20.61 -0.4% | 8/16/2020 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | | Low | View details for Brookline Capital Management rating of Kura Oncology (NASDAQ:KURA) on 8/16/2020 |
VERU Veru | $1.01 +4.5% | 8/14/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 8/14/2020 |
ARCT Arcturus Therapeutics | $38.81 +0.9% | 8/11/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/11/2020 |
ATE Antibe Therapeutics | C$0.30 +13.5% | 7/15/2020 | Reiterated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | N/A | View details for Brookline Capital Management rating of Antibe Therapeutics (TSE:ATE) on 7/15/2020 |
MRNA Moderna | $142.55 -5.9% | 7/13/2020 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | $95.00 | High | View details for Brookline Capital Management rating of Moderna (NASDAQ:MRNA) on 7/13/2020 |
ASRT Assertio | $0.99 +6.4% | 6/3/2020 | Initiated by | Brookline Capital Management | - | Buy | $3.50 | Low | View details for Brookline Capital Management rating of Assertio (NASDAQ:ASRT) on 6/3/2020 |
OTLK Outlook Therapeutics | $7.07 -2.1% | 5/5/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of Outlook Therapeutics (NASDAQ:OTLK) on 5/5/2020 |
DARE Daré Bioscience | $0.41 -4.8% | 4/28/2020 | Initiated by | Brookline Capital Management | Analyst S. Yanchus | Buy | $7.50 | High | View details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 4/28/2020 |
EDSA Edesa Biotech | $4.33 -1.6% | 3/30/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $70.00 | High | View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 3/30/2020 |
CLPT ClearPoint Neuro | $5.43 -2.2% | 3/11/2020 | Reiterated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | High | View details for Brookline Capital Management rating of ClearPoint Neuro (NASDAQ:CLPT) on 3/11/2020 |
ARMP Armata Pharmaceuticals | $2.72 +0.7% | 3/13/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of Armata Pharmaceuticals (NYSEAMERICAN:ARMP) on 3/13/2020 |
CLPT ClearPoint Neuro | $5.43 -2.2% | 3/12/2020 | Initiated by | Brookline Capital Management | - | Buy | $15.00 | N/A | View details for Brookline Capital Management rating of ClearPoint Neuro (NASDAQ:CLPT) on 3/12/2020 |
MNPR Monopar Therapeutics | $0.61 -0.2% | 2/19/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $42.00 | High | View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 2/19/2020 |
BIOX Bioceres Crop Solutions | $11.78 +4.1% | 2/4/2020 | Reiterated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | N/A | View details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 2/4/2020 |
MDNA Medicenna Therapeutics | C$2.85 +22.8% | 11/19/2019 | Reiterated by | Brookline Capital Management | - | Buy | C$4.00 | N/A | View details for Brookline Capital Management rating of Medicenna Therapeutics (TSE:MDNA) on 11/19/2019 |
SCYX SCYNEXIS | $2.41 +2.6% | 8/19/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 8/19/2019 |
VXRT Vaxart | $0.82 +0.1% | 8/15/2019 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $6.00 | Low | View details for Brookline Capital Management rating of Vaxart (NASDAQ:VXRT) on 8/15/2019 |
VERU Veru | $1.01 +4.5% | 7/29/2019 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $12.00 | High | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 7/29/2019 |
CLRB Cellectar Biosciences | $3.09 +1.6% | 7/29/2019 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $60.00 -> $60.00 | High | View details for Brookline Capital Management rating of Cellectar Biosciences (NASDAQ:CLRB) on 7/29/2019 |
ARCT Arcturus Therapeutics | $38.81 +0.9% | 7/24/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 7/24/2019 |
SCYX SCYNEXIS | $2.41 +2.6% | 1/4/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 1/4/2019 |
CLRB Cellectar Biosciences | $3.09 +1.6% | 11/20/2018 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Cellectar Biosciences (NASDAQ:CLRB) on 11/20/2018 |
ARCT Arcturus Therapeutics | $38.81 +0.9% | 9/27/2018 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 9/27/2018 |
TNXP Tonix Pharmaceuticals | $0.16 -4.2% | 7/27/2018 | Downgraded by | Brookline Capital Management | Analyst K. Raja | Buy -> Hold | | Low | View details for Brookline Capital Management rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 7/27/2018 |
TNXP Tonix Pharmaceuticals | $0.16 -4.2% | 5/1/2018 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 5/1/2018 |